Tykerb Tablet is formulated using lapatinib as main ingredient which is known to have highly efficient anti-cancerous activity against certain kinds of cancers. Being dual kinase inhibitor, it stops activity of HER2/neu & EGFR pathways. This tablet is most commonly utilized in combination therapy for HER-2 positive breast cancer. Tykerb Tablet is mainly metabolized by CYP3A4 enzyme in liver with superior protein binding abi9lity of more than 99%.
Has elimination half life of about 24 hours with repeated doses
Excreted in feces
Can also be used for metastatic breast cancer conditions